Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;13(12):3175-3188.
doi: 10.1007/s40123-024-01059-x. Epub 2024 Oct 26.

Micropulse Laser versus Eplerenone for Chronic Central Serous Chorioretinopathy: A 12-Month Comparison

Pasquale Viggiano #  1 , Giacomo Boscia #  2 , Enrico Borrelli  3 , Federica Evangelista  4 , Ermete Giancipoli  5 , Rodolfo Mastropasqua  6 , Alberto Quarta  6 , Maria Oliva Grassi  2 , Raffaella Aloia  6 , Giovanni Alessio  2 , Lisa Toto #  6 , Francesco Boscia #  2
Affiliations

Micropulse Laser versus Eplerenone for Chronic Central Serous Chorioretinopathy: A 12-Month Comparison

Pasquale Viggiano et al. Ophthalmol Ther. 2024 Dec.

Abstract

Introduction: To compare the long-term efficacy of navigated subthreshold micropulse laser (NSML) and continuous oral eplerenone (EPL) in chronic central serous chorioretinopathy (cCSC).

Methods: This retrospective observational study included 44 eyes with cCSC (EPL: n = 26; NSML: n = 18). Best-corrected visual acuity (BCVA), central macular thickness (CMT), subretinal fluid (SRF) height, and subfoveal choroidal thickness (SFCT) were evaluated over 12 months.

Results: Both groups showed significant improvements in BCVA and CMT (p < 0.05). Complete SRF resolution was achieved in both groups by 12 months, with NSML showing faster resolution (2.77 ± 1.43 vs. 6.34 ± 2.17 months, p < 0.001). The EPL group demonstrated significant SFCT reduction at 6 and 12 months (p = 0.001), while the NSML group showed no significant SFCT changes (p > 0.05).

Conclusions: Both NSML and EPL improved retinal morphology and visual function in patients with cCSC. NSML achieved faster SRF resolution, while EPL resulted in more significant choroidal thickness reduction. These findings suggest distinct mechanisms of action: NSML primarily affects the retinal pigment epithelium, while EPL modulates choroidal vasculature. Treatment choice may depend on individual patient characteristics and treatment goals.

Keywords: Central serous chorioretinopathy; OCT; Optical coherence tomography; Pachychoroid; Subfoveal choroidal thickness.

PubMed Disclaimer

Conflict of interest statement

Declarations Conflict of Interest Pasquale Viggiano, Giacomo Boscia, Enrico Borrelli, Federica Evangelista, Maria Oliva Grassi, Ermete Giancipoli, Rodolfo Mastropasqua, Alberto Quarta, Raffaella Aloia, Giovanni Alessio, Lisa Toto, and Francesco Boscia declare that they have no conflict of interest. Ethical Approval This retrospective study was conducted in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments between January 2021 and May 2023. In Italy, retrospective studies using anonymized data do not require specific patient consent or ethical committee approval. However, this study was reviewed and approved by the internal review boards of the University of Bari “Aldo Moro” and the University of “G. d’Annunzio” Chieti-Pescara. Despite the retrospective nature of the study, informed consent was obtained from all participants for the use of their clinical data for research purposes.

Figures

Fig. 1
Fig. 1
The changes in subfoveal choroidal thickness (SFCT) in both groups. In the case of patients with chronic central serous chorioretinopathy (cCSC) treated with navigated subthreshold microsecond pulse laser (NSML), no significant reduction in SFCT was observed at the 6-month or 1-year follow-up (A). On the other hand, patients with cCSC treated with continuous EPL (50 mg/daily) showed a significant decrease in SFCT at 6 months, and this reduction continued even further at 12 months (B)
See this image and copyright information in PMC

References

    1. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115:169–73. - PubMed
    1. Van RTJ, Van DEHC, Yzer S, Ohno-matsui K, Keunen JEE, Schlingemann RO, et al. Progress in retinal and eye research central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73: 100770. - PubMed
    1. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol. 2013;41:201–14. - PubMed
    1. Dansingani KK, Balaratnasingam C, Naysan J, Freund KB. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina. 2016;36:499–516. - PubMed
    1. Loo RH, Scott IU, Flynn HW, Gass JDM, Murray TG, Lewis M, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19–24. - PubMed

LinkOut - more resources